NAMSA, a portfolio company of ArchiMed since September 2020, announced on July 18 its acquisition of Germany-based CRI. The addition of CRI to NAMSA is a significant move for NAMSA in Germany that enhances and expands its CRO offerings throughout Europe and across all markets. The price and terms of the transaction are undisclosed.
CRI, The Clinical Research Institute, is a German-based full-service contract research organization (CRO) for phase III and IV clinical trials.
NAMSA is a global medical device research company providing a range of services to improve efficacy, non-clinical and clinical safety of medical devices, IVDs and combination products.
According to data captured in the LevinPro HC database, this transaction marks the 20th CRO transaction of the year. This also marks NAMSA’s first transaction of 2023. In 2022, it expanded its scale in the United Kingdom with the purchase of Perfectus Biomed Group in October for an undisclosed price.
